Not Yet Recruiting PHASE2 INTERVENTIONAL 7-arm
NCT07120984
A Study to Evaluate the Safety and Efficacy of L19TNF With Alkylating Chemotherapy for Patients With Recurrent IDH-mutant Astrocytoma or Oligodendroglioma (IMAGLIO)
A Phase II Study to Evaluate the Safety and Efficacy of L19TNF With Alkylating Chemotherapy for Patients With Recurrent IDH-mutant Astrocytoma or Oligodendroglioma
Sponsor: Philogen S.p.A.
Conditions
Glioma
Interventions
L19TNF L19TNF and CCNU L19TNF and CCNU in recurrent astrocytoma L19TNF and TMZ L19TNF and TMZ in recurrent astrocytoma L19TNF monotherapy L19TNF monothery in recurrent oligodendroglioma
Updated 1 time since 2025 Last updated: Aug 6, 2025 Started: Jan 30, 2026 Primary completion: Jan 30, 2029 Completion: Jan 30, 2029
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.
A PHASE2 clinical study on Glioma, this trial is actively recruiting participants. The trial is conducted by Philogen S.p.A. and has accumulated 1 data snapshot since 2026. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
1 version recorded Not Yet Recruiting — PHASE2
[monthly]
Eligibility Summary
No eligibility information available.
Contact Information
Sponsor contact:
- Philogen S.p.A.
Data source: Philogen S.p.A.
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
No location information available.